While sensitivity differed between cell models, at least two of the three HNSCC models were sensitive (>60% inhibition at 500 nM) to a group of six drugs including adavosertib (WEE1), alisertib (AURKA), danusertib (AURKA and AURKB), prexasertib (CHK1), reversine (MPS1), and BI 2536 (PLK1). Here, CHEK1 is linked to head and neck squamous cell carcinoma.